Details of the Drug

General Information of Drug (ID: DMOSW35)

Drug Name
Felodipine
Synonyms
Agon; Felobeta; Felocor; Feloday; Felodipina; Felodipinum; Felodur; Felogamma; Felogard; Fensel; Flodil; Hydac; Lexxel; Logimax; Modip; Munobal; Penedil; Perfudal; Plandil; Plendil; Preslow; Prevex; Renedil; Splendil; AGON SR; AbZ Brand of Felodipine; Aliud Brand of Felodipine; Alphapharm Brand of Felodipine; Alpharma Brand of Felodipine; Astra Brand of Felodipine; AstraZeneca Brand of Felodipine; Aventis Brand of Felodipine; Azupharma Brand of Felodipine; BC Brand of Felodipine; Betapharm Brand of Felodipine; Ct Arzneimittel Brand of Felodipine; Felo Biochemie; Felo Puren; Felodipin AL; Felodipin AZU; Felodipin AbZ; Felodipin Heumann; Felodipin Stada; Felodipin dura; Felodipin ratiopharm; Felodipin von ct; FelodurER; Heumann Brand of Felodipine; Hexal Brand of Felodipine; Hoechst Brand of Felodipine; Merck dura Brand of Felodipine; Munobal Retard; Pharmaceutica Astra Brand of Felodipine; Pharmacia Spain Brandof Felodipine; Plendil Depottab; Plendil ER; Plendil Retard; Promed Brand of Felodipine; Ratiopharm Brand of Felodipine; Stadapharm Brand of Felodipine; TheraPharm Brand of Felodipine; Worwag Brand of Felodipine; F 9677; Felodipin 1A Pharma; H 154 82; H 15482; CGH-869; Ct-Arzneimittel Brand of Felodipine; Dl-Felodipine; Felo-Puren; Felodipin-ratiopharm; Felodipina [INN-Spanish]; Felodipinum [INN-Latin]; H 154-82; H 154/82; Heumann, Felodipin; Plendil (TN); AE-641/11429675; Felodipine [USAN:BAN:INN]; Felodipine [USAN:INN:BAN]; H-154/82; Felodipine (JAN/USP/INN); Plendil, Renedil, Feloday, Felodipine; Ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; (+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; (+/-)-ethylmethyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate; 1A Brand of Felodipine; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methylester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-,ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester; 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate; 3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; 4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester; 4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester; 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester; 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 384.2
Topological Polar Surface Area (xlogp) 3.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [4]
Elimination
0.25% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 17.5 - 31.5 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.8666 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.0036% [4]
Vd
The volume of distribution (Vd) of drug is 10 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.001 mg/mL [3]
Chemical Identifiers
Formula
C18H19Cl2NO4
IUPAC Name
5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
InChI
InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
InChIKey
RZTAMFZIAATZDJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3333
ChEBI ID
CHEBI:585948
CAS Number
72509-76-3
DrugBank ID
DB01023
TTD ID
D0WN0U
VARIDT ID
DR00691
INTEDE ID
DR0685
ACDINA ID
D00267

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Blocker [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Felodipine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Felodipine and Acebutolol. Hypertension [BA00-BA04] [49]
Aliskiren DM1BV7W Moderate Decreased clearance of Felodipine due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [50]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Felodipine and Penbutolol. Hypertension [BA00-BA04] [49]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Felodipine and Nebivolol. Hypertension [BA00-BA04] [49]
Coadministration of a Drug Treating the Disease Different from Felodipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Felodipine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Idarubicin DMM0XGL Moderate Decreased clearance of Felodipine due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [52]
Arn-509 DMT81LZ Major Increased metabolism of Felodipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [53]
Emapalumab DMZG5WL Moderate Altered metabolism of Felodipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [54]
Siltuximab DMGEATB Moderate Altered metabolism of Felodipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [54]
Posaconazole DMUL5EW Moderate Decreased metabolism of Felodipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [55]
Aminophylline DML2NIB Minor Altered absorption of Felodipine caused by Aminophylline. Asthma [CA23] [56]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Felodipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Felodipine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Felodipine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Felodipine and Cariprazine. Bipolar disorder [6A60] [59]
Erdafitinib DMI782S Moderate Increased metabolism of Felodipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [60]
Talazoparib DM1KS78 Moderate Decreased clearance of Felodipine due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [61]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Felodipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Tucatinib DMBESUA Moderate Decreased metabolism of Felodipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [63]
Oxtriphylline DMLHSE3 Minor Altered absorption of Felodipine caused by Oxtriphylline. Cough [MD12] [56]
Lumacaftor DMCLWDJ Major Increased metabolism of Felodipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [53]
Ivacaftor DMZC1HS Moderate Decreased clearance of Felodipine due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [64]
MK-8228 DMOB58Q Moderate Decreased metabolism of Felodipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [65]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Felodipine caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [66]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Felodipine and Selegiline. Depression [6A70-6A7Z] [67]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Felodipine and Isocarboxazid. Depression [6A70-6A7Z] [67]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Felodipine and OPC-34712. Depression [6A70-6A7Z] [59]
Cenobamate DMGOVHA Moderate Increased metabolism of Felodipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [68]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Felodipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [69]
Phenobarbital DMXZOCG Moderate Increased metabolism of Felodipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [69]
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Felodipine and Nadolol. Essential hypertension [BA00] [49]
Tazemetostat DMWP1BH Moderate Increased metabolism of Felodipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [70]
Itraconazole DMCR1MV Major Decreased metabolism of Felodipine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [71]
Miconazole DMPMYE8 Moderate Decreased metabolism of Felodipine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [55]
Ketoconazole DMPZI3Q Major Decreased metabolism of Felodipine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [71]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Felodipine and Metipranolol. Glaucoma [9C61] [72]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Felodipine and Levobetaxolol. Glaucoma [9C61] [72]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Felodipine and Levobunolol. Glaucoma [9C61] [72]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Felodipine and Carvedilol. Heart failure [BD10-BD1Z] [49]
Boceprevir DMBSHMF Moderate Decreased metabolism of Felodipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [73]
Simeprevir DMLUA9D Moderate Decreased metabolism of Felodipine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [74]
Telaprevir DMMRV29 Moderate Decreased metabolism of Felodipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [73]
Rifampin DMA8J1G Major Increased metabolism of Felodipine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [53]
Rifapentine DMCHV4I Major Increased metabolism of Felodipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [53]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Felodipine and Procarbazine. Hodgkin lymphoma [2B30] [67]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Felodipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Felodipine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [76]
Saquinavir DMG814N Moderate Decreased metabolism of Felodipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [77]
Etravirine DMGV8QU Moderate Increased metabolism of Felodipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [78]
Atazanavir DMSYRBX Moderate Decreased metabolism of Felodipine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [79]
Lesinurad DMUR64T Moderate Increased metabolism of Felodipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [80]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Felodipine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [81]
Amobarbital DM0GQ8N Moderate Increased metabolism of Felodipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [69]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Felodipine and ITI-007. Insomnia [7A00-7A0Z] [59]
Naloxegol DML0B41 Minor Decreased clearance of Felodipine due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [82]
PF-06463922 DMKM7EW Moderate Increased metabolism of Felodipine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [83]
Selpercatinib DMZR15V Moderate Decreased metabolism of Felodipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [54]
Idelalisib DM602WT Moderate Decreased metabolism of Felodipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [84]
GDC-0199 DMH0QKA Major Decreased clearance of Felodipine due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [85]
IPI-145 DMWA24P Moderate Decreased metabolism of Felodipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [86]
Arry-162 DM1P6FR Moderate Decreased clearance of Felodipine due to the transporter inhibition by Arry-162. Melanoma [2C30] [85]
LGX818 DMNQXV8 Moderate Increased metabolism of Felodipine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [87]
Exjade DMHPRWG Moderate Decreased metabolism of Felodipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [88]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Felodipine and Thalidomide. Multiple myeloma [2A83] [85]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Felodipine and Siponimod. Multiple sclerosis [8A40] [85]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Felodipine and Fingolimod. Multiple sclerosis [8A40] [89]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Felodipine and Ozanimod. Multiple sclerosis [8A40] [90]
Romidepsin DMT5GNL Moderate Decreased clearance of Felodipine due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [91]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Felodipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [54]
Nilotinib DM7HXWT Moderate Decreased metabolism of Felodipine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [92]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Felodipine and Promethazine. Nausea/vomiting [MD90] [59]
Entrectinib DMMPTLH Moderate Decreased metabolism of Felodipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [93]
S-297995 DM26IH8 Moderate Decreased clearance of Felodipine due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [54]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Felodipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [94]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Felodipine and Safinamide. Parkinsonism [8A00] [67]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Felodipine and Rasagiline. Parkinsonism [8A00] [67]
Abametapir DM2RX0I Moderate Decreased metabolism of Felodipine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [95]
Lefamulin DME6G97 Moderate Decreased metabolism of Felodipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [96]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Felodipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [97]
Enzalutamide DMGL19D Major Increased metabolism of Felodipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [53]
Silodosin DMJSBT6 Moderate Decreased clearance of Felodipine due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [98]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Felodipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [54]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Felodipine and Levomepromazine. Psychotic disorder [6A20-6A25] [59]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Felodipine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [99]
Tocilizumab DM7J6OR Moderate Altered metabolism of Felodipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [54]
Canakinumab DM8HLO5 Moderate Altered metabolism of Felodipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [54]
Rilonacept DMGLUQS Moderate Altered metabolism of Felodipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [54]
Golimumab DMHZV7X Moderate Altered metabolism of Felodipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [54]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Felodipine and Quetiapine. Schizophrenia [6A20] [59]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Felodipine and Aripiprazole. Schizophrenia [6A20] [59]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Felodipine and Iloperidone. Schizophrenia [6A20] [59]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Felodipine and Paliperidone. Schizophrenia [6A20] [59]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Felodipine and Molindone. Schizophrenia [6A20] [59]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Felodipine and Thiothixene. Schizophrenia [6A20] [59]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Felodipine and Amisulpride. Schizophrenia [6A20] [59]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Felodipine and Asenapine. Schizophrenia [6A20] [59]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Felodipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [100]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Felodipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [54]
Larotrectinib DM26CQR Moderate Decreased metabolism of Felodipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [85]
Armodafinil DMGB035 Moderate Increased metabolism of Felodipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [85]
LEE011 DMMX75K Moderate Decreased metabolism of Felodipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [101]
Pitolisant DM8RFNJ Moderate Increased metabolism of Felodipine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [54]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Felodipine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [102]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Felodipine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [94]
Apixaban DM89JLN Moderate Decreased clearance of Felodipine due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [54]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Felodipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [103]
⏷ Show the Full List of 102 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Propyl gallate E00075 4947 Antimicrobial preservative; Antioxidant
Quinoline yellow WS E00309 24671 Colorant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Aluminum silicate E00587 56841952 Adsorbent; Diluent; Suspending agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Calcium silicate E00533 21910000 Adsorbent; Anticaking agent; Diluent; Opacifying agent
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hydrogenated polyoxyl 40 castor oil E00662 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Hypromellose E00634 Not Available Coating agent
Kaolin E00586 56841936 Adsorbent; Diluent; Suspending agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium aluminum silicate E00462 3084116 Adsorbent; Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium aluminosilicate E00349 19758701 Anticaking agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Felodipine 2.5 mg tablet 2.5 mg 24 HR Extended Release Oral Tablet Oral
Felodipine 10 mg tablet 10 mg 24 HR Extended Release Tablet Oral
Felodipine 10 mg tablet 10 mg 24 HR Extended Release Oral Tablet Oral
Felodipine 5 mg tablet 5 mg 24 HR Extended Release Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4190).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075896.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
9 The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349.
10 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
11 Drug Interactions Flockhart Table
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
22 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
23 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
24 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
25 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
26 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
28 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
29 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
30 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
31 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
32 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
33 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
34 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
35 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
36 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
37 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
38 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
39 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
40 Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
41 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
42 RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
43 Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
44 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
45 Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
46 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
47 Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
48 Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
49 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
50 Canadian Pharmacists Association.
51 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
52 Multum Information Services, Inc. Expert Review Panel.
53 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
54 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
55 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
56 Bratel T, Billing B, Dahlqvist R "Felodipine reduces the absorption of theophylline in man." Eur J Clin Pharmacol 36 (1989): 481-5. [PMID: 2753066]
57 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
58 Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD "Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice." Clin Pharmacol Ther 60 (1996): 25-33. [PMID: 8689808]
59 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
60 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
61 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
64 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
65 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
66 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
67 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
68 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
69 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
70 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
71 Jalava KM, Olkkola KT, Neuvonen PJ "Itraconazole greatly increases plasma concentrations and effects of felodipine." Clin Pharmacol Ther 61 (1997): 410-5. [PMID: 9129558]
72 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
73 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
74 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
75 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
76 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
77 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
78 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
79 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
80 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
81 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
82 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
83 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
84 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
85 Cerner Multum, Inc. "Australian Product Information.".
86 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
87 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
88 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
89 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
90 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
91 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
92 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
93 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
94 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
95 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
96 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
97 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
98 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
99 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
100 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
101 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
102 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
103 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.